Cargando…

Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma

In transplant-eligible patients who undergo upfront autologous stem cell transplant (ASCT) for multiple myeloma (MM), standard practice is to treat with six to eight cycles of induction therapy followed by high-dose chemotherapy with ASCT. A gap between the end of induction and the day of ASCT exist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bao, Alicia, Zhao, Qiuhong, Kudalkar, Ruchi, Rodriguez, Jose, Sharma, Nidhi, Bumma, Naresh, Devarakonda, Srinivas S., Khan, Abdullah M., Umyarova, Elvira, Rosko, Ashley E., Benson, Don, Cottini, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405820/ https://www.ncbi.nlm.nih.gov/pubmed/37554170 http://dx.doi.org/10.3389/fonc.2023.1216461

Ejemplares similares

Modified carfilzomib dosing is associated with improved treatment responses and longer time on treatment in patients with multiple myeloma
por: Khan, Abdullah M., et al.
Publicado: (2023)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
por: Nunnelee, Jordan, et al.
Publicado: (2022)

Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
por: Cottini, Francesca, et al.
Publicado: (2021)

Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma
por: Ozga, Michael, et al.
Publicado: (2023)

AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
por: Ozga, Michael, et al.
Publicado: (2020)

Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
por: Petrilla, Cole, et al.
Publicado: (2023)

Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant
por: Sigmund, Audrey M., et al.
Publicado: (2022)

AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival
por: Ozga, Michael, et al.
Publicado: (2020)

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias
por: Braunstein, Zachary, et al.
Publicado: (2022)

Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Role of Stem Cell Transplantation in Multiple Myeloma
por: Devarakonda, Srinivas, et al.
Publicado: (2021)

Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift
por: Wall, Sarah A., et al.
Publicado: (2022)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma
por: Kansagra, Ankit, et al.
Publicado: (2022)

Coexisting multiple myeloma, lymphoma, and non-small cell lung cancer: a case report and review of the literature
por: Khade, Parth, et al.
Publicado: (2017)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Induction chemotherapy before autologous stem cell transplantation for symptomatic plasma cell myeloma – does it matter?
por: Fung, Henry C, et al.
Publicado: (2010)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Characterization of monoclonal gammopathy of undetermined significance progression to multiple myeloma through meta-analysis of GEO data
por: Aljabban, Jihad, et al.
Publicado: (2023)

The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma
por: Min, Chang-Ki, et al.
Publicado: (2013)

PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma
por: McCourt, Orla, et al.
Publicado: (2020)

Fenestration of bone flap during interval autologous cranioplasty
por: Nguyen, Ha Son, et al.
Publicado: (2015)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
por: Minnie, Simone A., et al.
Publicado: (2021)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Pulmonary Haemosiderosis Secondary to Hereditary Haemochromatosis; a Case Report
por: Jehangir, Waqas, et al.
Publicado: (2020)

Daratumumab in Patients With Bortezomib-Refractory Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits
por: Almaani, Salem, et al.
Publicado: (2021)

Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma
por: Mian, Hira, et al.
Publicado: (2020)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Atypical metastasis of renal cell carcinoma to the uvula: case report and review of literature
por: Khade, Parth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0visiggnp6mvkcbt4hmmr4t5t1